Adaptive Design for a Confirmatory Basket Trial in Multiple Tumor Types Based on a Putative Predictive Biomarker

The Bayesian basket design for genomic variant-driven phase II trials

(2016) Richard Simon et al.   SEMINARS IN ONCOLOGY

Complementary versus companion diagnostics: apples and oranges?

(2015) Christopher-Paul Milne et al.   Biomarkers in Medicine

The Signature Program: Bringing the Protocol to the Patient

(2015) BP Kang et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

NCI-MATCH trial pushes cancer umbrella trial paradigm

(2015) Asher Mullard   NATURE REVIEWS DRUG DISCOVERY

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Beyond Histology: Translating Tumor Genotypes into Clinically Effective Targeted Therapies

(2014) C. B. Meador et al.   CLINICAL CANCER RESEARCH

The dream and reality of histology agnostic cancer clinical trials

(2014) Denis Lacombe et al.   Molecular Oncology

Designing Transformative Clinical Trials in the Cancer Genome Era

(2013) Stefan Sleijfer et al.   JOURNAL OF CLINICAL ONCOLOGY

Emerging landscape of oncogenic signatures across human cancers

(2013) Giovanni Ciriello et al.   NATURE GENETICS

Systematic Identification of Combinatorial Drivers and Targets in Cancer Cell Lines

(2013) Adel Tabchy et al.   PLoS One

Rare Cancer Successes Spawn 'Exceptional' Research Efforts

(2013) J. Kaiser   SCIENCE

Adaptive Licensing: Taking the Next Step in the Evolution of Drug Approval

(2012) H-G Eichler et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR

(2012) Anirudh Prahallad et al.   NATURE

Primed for resistance

(2012) David B. Solit et al.   NATURE

Impact of genetic dynamics and single-cell heterogeneity on development of nonstandard personalized medicine strategies for cancer

(2012) R. A. Beckman et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

AKT Inhibition Relieves Feedback Suppression of Receptor Tyrosine Kinase Expression and Activity

(2011) Sarat Chandarlapaty et al.   CANCER CELL

Integrating predictive biomarkers and classifiers into oncology clinical development programmes

(2011) Robert A. Beckman et al.   NATURE REVIEWS DRUG DISCOVERY

Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation

(2011) Paul B. Chapman et al.   NEW ENGLAND JOURNAL OF MEDICINE

The BATTLE Trial: Personalizing Therapy for Lung Cancer

(2011) Edward S. Kim et al.   Cancer Discovery

Regional differences in multinational clinical trials: anticipating chance variation

(2010) Ian C Marschner   Clinical Trials

Efficiency of carcinogenesis: Is the mutator phenotype inevitable?

(2010) Robert A. Beckman   SEMINARS IN CANCER BIOLOGY

Cancer systems biology: a network modeling perspective

(2009) P. K. Kreeger et al.   CARCINOGENESIS

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

(2009) J. D. Wolchok et al.   CLINICAL CANCER RESEARCH

I-SPY 2: An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

(2009) AD Barker et al.   CLINICAL PHARMACOLOGY & THERAPEUTICS

Phase II, Open-Label Study Evaluating the Activity of Imatinib in Treating Life-Threatening Malignancies Known to Be Associated with Imatinib-Sensitive Tyrosine Kinases

(2008) M. C. Heinrich et al.   CLINICAL CANCER RESEARCH